ASSESSING DISEASE-SPECIFIC UTILITY IN RECURRENT GENITAL HERPES (RGH)

Author(s)

Doward LC1, McKenna SP1, Meads DM1, Ratcliffe J2, Langley PC3, 1Galen Research, Manchester, United Kingdom; 2Research Triangle Institute, Manchester, UK; 33M Pharmaceuticals, St Paul, MN, USA

OBJECTIVES: Utility calculation generally relies on the use of generic measures that assess health status. Evidence suggests that such measures have limited responsiveness - largely because the health states described are of limited relevance to any specific disease. Quality of life (QoL) assessment has shown that it is not health status itself that is important to patients but the impact that this might have on their lives. Consequently, it would appear more appropriate for utility to be determined by preference for different QoL states, particularly in Quality Adjusted Life Year (QALY) type analyses. The present study was designed to determine QoL-based utilities specific to RGH. METHODS: Discrete choice conjoint analysis (CA) and time trade off (TTO) exercises were conducted using QoL states generated from six items from the RGH Quality of Life Questionnaire (RGHQoL). RGH patients completed tasks via interview. RESULTS: One hundred ninety-two interviews were conducted (79 male, 113 female; age range 19-69 years, mean age 38.4). For CA, all attributes were statistically significantly influential in determining preferences. The application of the random effects probit model produced coefficient values that can be used as preference weights. For the TTO exercise, coefficient values (preference weights) were derived by application of the random effects tobit regression model. These coefficient values can be used to derive relative and absolute utility values respectively. As the TTO technique possesses cardinal properties, QALY scores can also be calculated. CONCLUSIONS: It is feasible to generate both relative and absolute utility values from responses to the RGHQoL questionnaire, allowing utility to be based on true QoL. The ability to derive disease-specific QoL-based utilities in this way means that the same instrument can be used to generate both QoL and utility data from the same clinical trial.

Conference/Value in Health Info

2003-05, ISPOR 2003, Arlington, VA, USA

Value in Health, Vol. 6, No. 3 (May/June 2003)

Code

PIN51

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×